Silence Therapeutics (SLN) Operating Income (2020 - 2025)
Historic Operating Income for Silence Therapeutics (SLN) over the last 7 years, with Q3 2025 value amounting to -$26.2 million.
- Silence Therapeutics' Operating Income rose 1251.13% to -$26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.0 million, marking a year-over-year decrease of 1031.26%. This contributed to the annual value of -$63.3 million for FY2024, which is 165.26% up from last year.
- According to the latest figures from Q3 2025, Silence Therapeutics' Operating Income is -$26.2 million, which was up 1251.13% from -$24.0 million recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' Operating Income ranged from a high of -$12880.5 in Q1 2021 and a low of -$30.0 million during Q3 2024
- For the 5-year period, Silence Therapeutics' Operating Income averaged around -$16.5 million, with its median value being -$16.1 million (2023).
- In the last 5 years, Silence Therapeutics' Operating Income tumbled by 13704901.42% in 2021 and then surged by 7363.4% in 2024.
- Over the past 5 years, Silence Therapeutics' Operating Income (Quarter) stood at -$15.2 million in 2021, then increased by 15.32% to -$12.9 million in 2022, then decreased by 28.39% to -$16.5 million in 2023, then skyrocketed by 73.63% to -$4.4 million in 2024, then plummeted by 503.03% to -$26.2 million in 2025.
- Its Operating Income stands at -$26.2 million for Q3 2025, versus -$24.0 million for Q2 2025 and -$28.4 million for Q1 2025.